Next Article in Journal
Complementary Role of CD4+ T Cells in Response to Pneumococcal Polysaccharide Vaccines in Humans
Next Article in Special Issue
Pneumococcal Vaccines: Challenges and Prospects
Previous Article in Journal
Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein
Previous Article in Special Issue
PCV7- and PCV10-Vaccinated Otitis-Prone Children in New Zealand Have Similar Pneumococcal and Haemophilus influenzae Densities in Their Nasopharynx and Middle Ear
Article Menu

Export Article

Open AccessArticle
Vaccines 2019, 7(1), 17; https://doi.org/10.3390/vaccines7010017

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children

1
Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, WA 6009, Australia
2
Division of Paediatrics, School of Medicine, University of Western Australia, Crawley, WA 6009, Australia
3
Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea
4
School of Public Health, University Centre for Rural Health (USRH), The University of Sydney, Lismore, NSW 2480, Australia
5
School of Biomedical Sciences, University of Western Australia, Crawley, WA 6009, Australia
6
Centre for Biostatistics, Telethon Kids Institute, Nedlands, WA 6009, Australia
*
Authors to whom correspondence should be addressed.
These first authors contributed equally to this work.
These senior authors contributed equally to this work.
§
Full team listed under acknowledgements.
Received: 29 November 2018 / Revised: 30 January 2019 / Accepted: 30 January 2019 / Published: 4 February 2019
(This article belongs to the Special Issue Vaccines for Pneumococcal Infections)
Full-Text   |   PDF [2002 KB, uploaded 8 February 2019]   |  
  |   Review Reports

Abstract

We investigated the immunogenicity, seroprotection rates and persistence of immune memory in young children at high risk of pneumococcal disease in Papua New Guinea (PNG). Children were primed with 10-valent (PCV10) or 13-valent pneumococcal conjugate vaccines (PCV13) at 1, 2 and 3 months of age and randomized at 9 months to receive PPV (PCV10/PPV-vaccinated, n = 51; PCV13/PPV-vaccinated, n = 52) or no PPV (PCV10/PPV-naive, n = 57; PCV13/PPV-naive, n = 48). All children received a micro-dose of PPV at 23 months of age to study the capacity to respond to a pneumococcal challenge. PPV vaccination resulted in significantly increased IgG responses (1.4 to 10.5-fold change) at 10 months of age for all PPV-serotypes tested. Both PPV-vaccinated and PPV-naive children responded to the 23-month challenge and post-challenge seroprotection rates (IgG ≥ 0.35 μg/mL) were similar in the two groups (80–100% for 12 of 14 tested vaccine serotypes). These findings show that PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses. Priming with currently available PCVs followed by a PPV booster in later infancy could offer improved protection to young children at high risk of severe pneumococcal infections caused by a broad range of serotypes. View Full-Text
Keywords: pneumococcal polysaccharide vaccine; pneumococcal conjugate vaccine; S. pneumoniae; antibodies; immune memory; Papua New Guinea pneumococcal polysaccharide vaccine; pneumococcal conjugate vaccine; S. pneumoniae; antibodies; immune memory; Papua New Guinea
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

van den Biggelaar, A.H.J.; Pomat, W.S.; Masiria, G.; Wana, S.; Nivio, B.; Francis, J.; Ford, R.; Passey, M.; Kirkham, L.-A.; Jacoby, P.; Lehmann, D.; Richmond, P.; the 10v13v PCV Trial Team. Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with 10-Valent or 13-Valent Pneumococcal Conjugate Vaccine: A Randomized Controlled Trial in Papua New Guinean Children. Vaccines 2019, 7, 17.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top